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Abstract: A new fluorescent method was developed based on the ulifloxacin-europium (ill )-sodium dodecylbenzene
sulfonate system for the determination of ulifloxacin, the active metabolite of prulifloxacin. Sodium dodecylbenzene
sulfonate formed a ternary complex with ulifloxacin-europium (ill) and significantly enhanced the characteristic
fluorescence of europium (ill). The enhanced fluorescence intensity showed a good linear relationship with the
concentration of ulifloxacin in the range of 5.0 x 10- 8 - 2. 0 X10- 6 M with a detection limit of 2.0 x 10- 10 M (30). This
method is rapid and sensitive, and has been successfully applied to the determination of ulifloxacin in human urine and
serum samples.
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Figure 1 Chemical structures of ulifloxacin (UFX) and prulifloxacin (PUFX)
Prulifloxacin (PUFX, NM441 , Figure 1), the prodrug of
ulifloxacin (UFX, NM394 , Figure 1), is a broad-spectrum
oral fluoroquinolone antibacterial agent [1]. After oral
administration' and intestinal absorption, PUFX is rapidly
metabolized by paraoxonases into UFX, the active metabolite
of prulifloxacin [2-7]. Therefore, the in vitro antimicrobial
activity was studied using ulifloxacin [6, 8,9].
o
For the pharmacokinetic study of a prulifloxacin formu-
lation product in healthy volunteers, a rapid, selective and
sensitive analytical method is required to accurately deter-
mine the ulifloxacin concentration in body fluid. In previ-
ous studies, analysis of ulifloxacin has been performed by
high performance liquid chromatography ( HPLC) with
ultraviolet ( UV) detection [10], HPLC with fluorescence
detection [11], HPLC- MS/MS [12], capillary zone elec-
trophoresis [13], flow-injection chemiluminescence [14]
and terbium-sensitized second-order scattering spectrofluo-
rimetry [15].
Europium-sensitized fluorescent determination is an indi-
rect method involving complexation of ligand molecules and
europium ions. The intramolecular energy transfer from the
absorbing ligand to the europium ions results in the emission
of a strong narrow-band fluorescence with a large Stokes
shift and long decay time. As a result, it could avoid the
potential background fluorescent interferences from the
biological matrix [16]. Quinolones and f1uoroquinolones
have suitable functional groups
(carboxylic and ketO-oxygen atoms) to
form stable complexes with lanthanide
ions. This technique has been widely
utilized for the determination of quin-
olones norfloxacin [17] , enoxacin
[18], garenoxacin [19], ciprofloxacin
[20], and trovafloxacin [21]. But the
sensitivity is not very high as all the
detection limits of these methods are
over the range of 1. 2 x 10- 9 to 4.7 x
10- 8 M. However, the europium-sensi-
tized fluorescent determination method described here could
provide a much higher sensitivity. The detection limit (3a)
could attain 2.0 x 10- 10 M. Furthermore, there are few
reports about the fluorescence mechanism. Compared with
most of other approaches for the determination of UFX,
the proposed method offers advantages in higher sensitivity,
wider linear range, and better stability, which has been
successfully applied to the determination of ulifloxacin in
human urine and serum samples with satisfactory results,
and the fluorescence enhancement mechanism is also
discussed. To our knowledge, this is the first time that the
europium-sensitized fluorescent determination is utilized for
the determination of UFX.
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3 Results and discussion
3.1 Spectral characteristics
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Figure 2 Excitation spectra and emission spectra. Experimental con-
ditions: UFX, 5.0xlO- 6 M; Eir, 5.0xlO- 6 M; SDBS, 1.0xlO- 4
M; NH.CI-NJ-l,· H2 0, 0.01 M, pH= 8.6. 1, 1', UFX; 2, 2', Eu3+ ;
3, 3', UFX-Eu3 + ; 4, 4', UFX-Eu3 + -SDBS.
In order to study the interaction between UFX-Eu3 + and
SOBS, the ultraviolet absorption spectra were recorded (Fig-
ure 3), which showed that the absorption peak of UFX-Eu3 +
was at 267 nm. However, the absorbance of UFX-Eu3 +
increased apparently after the addition of the SOBS solution,
which was in accordance with the fluorescence enhancement
of the excitation spectra in the UFX-Eu3 + -SOBS system
(Figure 2). Also, the maximum absorption wavelength
underwent a red shift from 267 nm to 273 nm, indicating the
formation of a UFX-&r -SOBS ternary complex [22].
The excitation and emission spectra of UFX 0, 1'), Eu3 +
(2, 2'), UFX-Eu3 + (3, 3'), and UFX-Eu3 + -SOBS (4, 4')
system are shown in Figure 2. The excitation spectrum of
the UFX-Eu3 + -SOBS system exhibited a peak at 276 nm,
which was selected as the excitation wavelength. From the
emission spectra, no characteristic fluorescence of Eu3 + was
observed in the Eu3 + system (2'), while weak characteristic
fluorescence of Eu3 + was observed in the UFX-Eu3 + system
(3'). Curve 4' is the emission spectrum of UFX-Eu3 + -SOBS
system and strong emission peaks were observed at 594 and
616 nm, corresponding to transitions of the Eu3 + 500 _7F]
and 500 _7F2, respectively. Compared with the UFX-Eu3 +
system, the fluorescence intensity(h) was enhanced about
37-fold by the addition of SOBS. Thereby, 276 nm and 616
nm were chosen as the excitation wavelength and emission
wavelength, respectively.
centrifuging for 5 min at 1 500 X g [19]. No sample pre-
treatment was required for urine samples. Further dilution
with water was made to ensure that the concentrations of
the drug in the sample solutions fall within the linear range
of the method.
2 Materials and methods
2.1 Appara~
Fluorescence intensity was measured on an Hitachi F-2500
fluorescence spectrophotometer (Japan), using a standard
10 mm path-length quartz cell, with 10 nm bandwidths for
both the excitation and emission monochromators. Absorp-
tion spectra were measured on an UV-2401PC spectropho-
tometer (Shimadzu, Japan) equipped with 10 mm path-
length quartz cells. The surface tension was measured on a
Processor Tensiometer-Kl2 (KRUSS Corp., Germany)
with the, precise degree of 0.01 mN/m by the Wilhelmy
plate. The pH was measured using a Lei Ci pHs-3C pH-me-
ter (Shanghai, China). Serum samples were centrifuged
with a Xiang Yi TDZ4A-WS brachytely desk centrifuge
(Changsha, China).
2.2 Reagents
A standard stock solution (1. 0 X 10- 3 M) of UFX (purity,
100.9%, Department of Pharmacy, Beijing Hospital,
China) was prepared by dissolving 0.0349 g of UFX in
dilute hydrochloric acid and then diluting to 100 mL with
water. The solution was kept at 4'C in the refrigerator and
protected from light. Standard working solutions were pre-
pared by diluting the standard stock solution with water.
A solution of europium (III) (Eu3 + ) (1. 0 x 10- 3 M) was
prepared by dissolving 0.0176 g EU20.J(purity, 99.99%) in
hydrochloric acid solution 0 : 1) and evaporating the solu-
tion to near dryness before diluting to 100 mL with water.
The solution was kept at 4 ·C. The working solutions were
diluted with water.
A sodium dodecylbenzene sulfonate (SOBS) solution (2.0
X 10- 3 M) was prepared by dissolving O. 0774 g SOBS
(purity, 90.0%) in water and then diluting to 100 mL with
water.
A NHtCl-NH3 • H20 buffer solution (pH 8.6, 0.1 M)
was prepared by dissolving 1. 3508 g NHt CI in water to
250 mL and then adjusting pH to 8.6 with NKJ ·HzO.
All reagents used were of analytical grade unless other-
wise indicated. Redistilled water made in-house was used
throughout the study.
2.3 Methods
Various solutions were added (to a 10 mL volumetric flask)
according to the following order: O. 5 mL of 1. 0 X 10- 4 M
Eu3 + solution, an aliquot of UFX standard working solu-
tion, 0.5 mL of 2.0 X 10- 3 M SOBS solution, and 1.0 mL of
0.1 M NHtCl-NKJ 'H20 buffer solution (pH 8.6). The re-
sultant mixture was diluted to the volume with water and
mixed thoroughly by shaking, and then allowed to stand for
15 min at room temperature. Final UFX concentrations
were in the range of 5.0 X 10- 8 - 2.0 X 10- 6 M. The fluo-
rescence intensity was measured in a 10 mm path-length
quartz cell with excitation and emission wavelengths of 276
nm and 616 nm, respectively.
2.4 Preparation of serum and urine samples
1. 0 mL of each serum sample was deproteinized with 2.0
mL of acetonitrile, followed by vortexing for 5 min and
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Figure 3 Ultraviolet absorption spectra. Experimental conditions:
UFX. 1. 0 x 10- 5 M; Eu3 + • 4.0 X 10- 5 M; SDBS. 1. 0 x 10- 4 M;
NI-LCI-NI-lJ' ao. 0.01 M. pH= 8.6. 1, UFX-Eu3 + ; 2, UFX-Eu3 +-
SDBS.
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In order to investigate the effect of micellar media on the
fluorescence intensity, various types of surfactants including
CTAB (Cetrimonium bromide, cationic) , GA (Arabic
gum, non-ionic), OP (Polyoxyethylene nonylphenol ether,
non-ionic), l3-CD (l3-cyclodextrin, non-ionic), lriton X-
100 (non-ionic), Pluronic F68 (non-ionic), PEG40 (non-
ionic), SDS (Sodium dodecyl sulfate, anionic), and SDBS
(anionic) were studied (Table 1). It can be seen that there
was no significant fluorescence enhancement in the presence
of cationic surfactants, non-ionic surfactants or anionic sur-
factant SDS. However, a significant increase in fluores-
cence was observed in the presence of anionic surfactant
SDBS. The effect of the SDBS concentration on the fluo-
rescence intensity was also investigated (Figure 6). Maxi-
mum fluorescence intensity was observed at an SDBS con-
centration of 1. 0 X 10- 4 M, which was chosen for further
experiments.
The mechanism of SDBS effect was studied by investiga-
ting the changes of surface tension of the fluorescence sys-
tem with an increase of the SDBS concentration (Figure 7).
It can be seen that the surface tension first decreased sharply,
and then reached equilibrium at the SDBS concentration of
7.0 X 10- 5 M, which can be considered as the apparent crit-
ical micelle concentration (CMC) of SDBS in this system.
Since the SDBS concentration selected for the study (1. 0 X
10- 4 M) was well above the CMC, it could be concluded
that the formation of micelles had a great impact on the
enhancement of the fluorescence intensity of the system.
Figure 5 Effect of Eu3 + concentration. Experimental conditions:
UFX, 5.0xlO- 6 M; SDBS, 1.0xlO-'M; NI-LCI-NI-lJ·aO. 0.01
M, pH=8.6.
3.4 Effect of surfactants
3.3 Effect of europium (][) concentration
With a fixed UFX concentration of 5.0 X lO- sM, the effect
of Eu3 + concentration on the fluorescence intensity of the
system was investigated (Figure 5). Fluorescence intensity
reached a maximum value with a Eu3 + concentration of 5.0
xlO- 6 M. Therefore, the Eu3 + concentration of 5.0xlO- 6
M was selected for further experiments. b.IF was the net
fluorescence intensity, with the background signal being
subtracted.
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Figure4 Effect of pH. Experimental conditions: UFX, 5.0xIO- 6 M;
&jl+, 5.0xlO- 6 M; SDBS, 1.0xlO-'M.
3.2 Effects of pH and buffers
The effect of pH on the fluorescence intensity of the system
was studied in the range of 5.8 -10. 5. The results indicated
that the optimal pH value was in the range of 8.2 - 8. 8
(Figure 4), so pH 8.6 was selected for the recommended
procedure. Setting pH at 8.6, the effect of the following
buffer solutions on the fluorescence intensity was then
examined, including NtLAc-NH3 ' H2 0, NaAc-HAc,
NtLCl-NH3 ' HzO, Tris-HCl, and KH2 POr NaOH. It was
found that UFX-Eu3 + -SDBS fluorescence system in the
NtL Cl-NH3 • Hz° medium of the concentration O. 01 M
gave the highest sensitivity. Therefore, a 0.01 M NtLCl-
Nl-lJ .H20 buffer solution of pH 8.6 was chosen for further
study.
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Thble 1 Effects of different surfactants
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Change of 61
(%)
l.ox 10 7
4.0X 10- 7
l.5X 10- 6
5.0X 10- 6
2.0X 10- 5
5.0X 10- 5
l.ox 10-'
l.5x 10-'
2.0xlO-'
3.0X 10-'
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l.OX 10- 3
l.5X 10- 3
l.ox 10- 2
l.ox 10- 2
Maximum permissible
concentration (M)Interference species
Fe3 + , cr
Cu2 + , SO.z-
Vitamin C
Zn2 + , SO.z-
L-Methionine
AJ3+ , Cl-
L- Histidine
NH. + , Cl-
Mi+,Ct-
Ca2 + , Cl-
L-Glutamine
L-Cysteine
Glycine
Glucose
Na+ , Cl-
K+, Cl-
3.7 Analytical application
3.7.1 Linear range and detection limit
Under the optimal experimental conditions, the enhanced
fluorescence intensity of the system C~j.IF) responded linear-
ly to the UFX concentration in the range of 5.0 x 10- 8 -
2.0 x 10- 6 M with a correlation coefficient of 0.9990. The
detection limit for UFX calculated from the standard devia-
tion of the blank (the reagent blank without UFX, n =20)
(3a) is 2.0 X 10- 10 M.
In comparison with other methods reported, the rapid
and simple method proposed in this paper offers significant-
ly increased sensitivity (Table 3).
3.7.2 Recovery assay
The maximum concentration of UFX in the serum is
between 1. 0 ,uglmL (2.8 x 10- 6 M) and 1. 6 ,uglmL (4.6 X
10- 6 M) after a single oral administration of 300, 450 and
600 mg PUFX. In contrast, the concentration of UFX in
urine is very high after dosing, and can reach more than 60
,uglmL (1. 7 x 10- 4 M) [8].
In order to ensure that the concentrations of the drug fall
within the linear range of the method, urine samples were
3.6 Effect of interfering species
The interference of metal ions, glucose, and amino acids
which are commonly presented in vivo was studied by
adding different amounts of these compounds to a 5.0 x
10- 6 M UFX solution. The maximum permissible concen-
trations of the interfering substances causing a ±5% relative
error in the fluorescence intensity are shown in Table 2.
The results indicated that most species except for Cu2 + and
Fe3 + had little effect on the fluorescence intensity of the
system.
Thble 2 Maximum permissible concentration of interference species
experiments also demonstrated that the fluorescence intensity
of the system reached a maximum within 15 min after all
the reagents had been added and remained stable for at least
3 h.
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Figure 7 Effect on the solution surface tension with the addition of
SDBS. Experimental conditions: UFX, 5.0 x 10- 6 M; Eu3 + , 5.0 x
1O- 6 M; NH.Cl-N~ 'H,O, 0.01 M, pH=8.6.
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Figure 6 Effect of SDBS concentration. Experimental conditions:
UFX. 5.0 x 10- 6 M; Eu3 + , 5.0 X 10- 6 M; NH.Cl-N~·H,O. 0.01
M, pH=8.6.
3. 5 Effect of reagent addition sequence and fluorescence
stability
The effect of the reagent addition sequence on the fluores-
cence intensity was studied. The results showed that the
addition sequence of Etr , UFX, SOBS, and NIL Cl-NHa .
H2 0 provided the optimal performance. Therefore, this
addition sequence was chosen for further studies. The
Cetrimonium bromide (CD\B)
[tcyclodextrin ([teD)
Polyoxyethylene nonylphenol ether (OP)
'Iiiton X-100
Arabic gum (GA)
Pluronic F68
PEG40
Sodium dodecyl sulfate (SDS)
Sodium dodecylbenzene sulfonate (SDBS)
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diluted 1 OOO-foid with water and then analyzed by standard
addition method, and serum samples were deproteinized
Thble 3 Comparison of methods for the determination of UFX
first and then diluted 40-fold prior to analysis. The results
of spiked urine and serum samples are listed in Table 4.
Method Detection limit (M) Linear range (M) Application References
HPLC
HPLC-Flu
HPLC-MS
Capillary zone electrophoresis
Chemiluminescence
Terbium-sensitized second-order
scattering spectrofluorimetry
Europium probe spectrofluorimetry
1.7x10 8
5.5x10- 9
3.9 X 10- 9
2.0 X 10- 10
1.4x 10 8 -1. 7x 10- 6
2.9xlO- 8 -2.9xlO- 6
7.2x 10- 8 -l.4X 10- 5
5.7 X10- 8 - 5.7 X10- 6
LOx 10- 8 -5.0xlO- 6
2.0 X10- 8 -LOX 10- 5
5.0XlO- 8 -2.0xlO- 6
Aqueous human humor
Human plasma
Human plasma
Human plasma
Spiked human serum and urine
Spiked human serum and urine
Spiked human serum and urine
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